Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Merck
Medtronic
Daiichi Sankyo
Moodys
McKesson
Farmers Insurance
Fish and Richardson
Chinese Patent Office

Generated: February 21, 2019

DrugPatentWatch Database Preview

EGRIFTA Drug Profile

« Back to Dashboard

When do Egrifta patents expire, and what generic alternatives are available?

Egrifta is a drug marketed by Theratechnologies and is included in one NDA. There are five patents protecting this drug.

This drug has forty-four patent family members in sixteen countries.

The generic ingredient in EGRIFTA is tesamorelin acetate. One supplier is listed for this compound. Additional details are available on the tesamorelin acetate profile page.

Summary for EGRIFTA
International Patents:44
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
Clinical Trials: 10
Drug Prices: Drug price information for EGRIFTA
DailyMed Link:EGRIFTA at DailyMed
Drug patent expirations by year for EGRIFTA
Generic Entry Opportunity Date for EGRIFTA
Generic Entry Date for EGRIFTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EGRIFTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for EGRIFTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Deloitte
Johnson and Johnson
McKesson
Federal Trade Commission
Cipla
Healthtrust
Queensland Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.